Birinapant

DB11782InvestigationalSmall molecule

Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Chemical structure of Birinapant
Formula / weight
C42H56F2N8O6 · 806.957 g/mol (avg)

Resolves to

Compound
UNII6O4Z07B57RCAS1260251-31-7ChEMBLCHEMBL3039522PubChem49836020
Structure
InChIKeyPKWRMUKBEYJEIX-DXXQBUJASA-NSMILESCC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(NC2=CC(F)=CC=C12)C1=C(C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C2=CC=C(F)C=C2N1
Targets
Q13490BIRC2P98170XIAP

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Birinapant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In